Brief: Candel Therapeutics Receives FDA Fast Track Designation For Can-2409 In Non-Small Cell Lung Cancer
17/04/2023 13:02
April 17 (Reuters) - Candel Therapeutics Inc CADL.O :
* CANDEL THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION
FOR
CAN-2409 IN NON-SMALL CELL LUNG CANCER
* CANDEL THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION
FOR
CAN-2409 IN NON-SMALL CELL LUNG CANCER
* CANDEL THERAPEUTICS INC - EXPECTS TO PRESENT UPDATED
CLINICAL
DATA FROM ITS PHASE 2 CLINICAL TRIAL IN Q3 OF 2023
Source text for Eikon: ID:nGNX5LX4nS
Further company coverage: CADL.O
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)
Candel Therapeutics reports Q1 loss
Brief: Candel Therapeutics Q1 Net Income USD -8.861 Million
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec